Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Detroit mayor turned down J&J vaccine in favour of others

03/05/2021 | 04:24pm EDT

LANSING, Mich.Detroit this week turned down 6,200 doses of the newly authorized Johnson & Johnson coronavirus vaccine, favouring shots from Pfizer and Moderna, but said Friday it will accept J&J doses in the state's next allocation.

Mayor Mike Duggan had said Thursday that residents should get the “best” vaccines — from Moderna and Pfizer — conflicting with guidance from top state and federal health officials who caution against comparing the three vaccines and note all provide strong protection against the worst outcomes.

Duggan had also said the allotment of 29,000 Pfizer and Moderna doses “covered everyone who wanted a vaccination this week." On Friday, he called J&J vaccines "a key part of our expansion of vaccine centres.”

No other local health department declined any of the 82,700 J&J shots sent to Michigan this week, the state health department said.

Dr. Joneigh Khaldun, Michigan's chief medical executive, said earlier in the week that people who are offered the J&J vaccine should "take it because declining ... could be the difference between life and death.” In a statement Friday, she cited differences in when and where each company conducted its studies, with the Moderna and Pfizer research finished before concerning variants began spreading.

In the U.S., the two-dose Pfizer and Moderna shots were 95% protective against symptomatic COVID-19. J&J’s one-dose effectiveness of 85% against severe COVID-19 dropped to 66% when moderate cases were rolled in. The Food and Drug Administration has reported that, just like its predecessors, the J&J shot strongly safeguards against serious illness, hospitalization and death.

“All of the vaccines are safe and effective and I recommend that all vaccines be offered in all communities,” Khaldun said.

White House coronavirus special adviser Andy Slavitt said Friday that the White House talked to the Detroit mayor's office, which called the situation a “misunderstanding.”

“In fact, he is very eager for the Johnson & Johnson vaccine,” Slavitt said of Duggan.

As of Wednesday, 11% of Detroit residents age 16 and older had gotten at least one dose. The statewide rate was 19%.

Detroit this week expanded vaccinations to any resident who is a factory worker, no matter their age or where they work. Non-residents can also get a shot if they work in manufacturing in the city.

Detroit's 6,200 J&J doses went to health departments in counties with the lowest vaccination rates of people age 65 and up, state spokesman Bob Wheaton said.

J&J's vaccine is produced using a cell line derived from an aborted fetus, which has prompted moral concerns from Catholic leaders. The chairmen of the United States Conference of Catholic Bishops’ committees on doctrine and abortion issues said the Pfizer or Moderna vaccines are preferable “if one has the ability to choose a vaccine.”

A $4.2 billion COVID-19 relief plan approved by Michigan's Republican-led Legislature this week includes a provision that would require vaccine recipients to be informed if and in what manner their vaccine was developed with aborted fetal tissue or human embryonic stem cells. Democratic Gov. Gretchen Whitmer could declare the item unenforceable.


Associated Press writer Zeke Miller in Washington contributed to this report.


Follow David Eggert at https://twitter.com/DavidEggert00

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.15% 162.24 Delayed Quote.3.09%
MODERNA, INC. 6.84% 170.81 Delayed Quote.53.03%
PFIZER INC. 2.58% 38.57 Delayed Quote.2.15%
All news about JOHNSON & JOHNSON
04/16J&J, MORGAN STANLEY, COINBASE : Stocks That Defined the Week
04/16UPDATE : Street Color: Global Calendar For Week Ending April 23 (Includes Earnin..
04/16STREET COLOR : Johnson & Johnson Researchers State No Casual Link Has Yet Been F..
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
04/16STREET COLOR : US Won't Allocate Johnson & Johnson Vaccine Doses to States Next ..
04/16JOHNSON & JOHNSON  : South Africa takes first step to offer jabs to the elderly
04/16STREET COLOR : CDC Advisory Committee Will Meet Again April 23 to Discuss Recomm..
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
04/16WALL STREET STOCK EXCHANGE : Investor sentiment reaches new highs
04/16MARKET CHATTER : ISS Urges Investors To Vote Against General Electric CEO Bonus ..
More news
Financials (USD)
Sales 2021 92 323 M - -
Net income 2021 22 297 M - -
Net cash 2021 2 740 M - -
P/E ratio 2021 19,7x
Yield 2021 2,57%
Capitalization 427 B 427 B -
EV / Sales 2021 4,60x
EV / Sales 2022 4,32x
Nbr of Employees 134 500
Free-Float 83,5%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 181,33 $
Last Close Price 162,24 $
Spread / Highest target 23,9%
Spread / Average Target 11,8%
Spread / Lowest Target -5,70%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.09%427 130
ROCHE HOLDING AG0.06%289 376
PFIZER INC.2.15%215 150
NOVARTIS AG-3.32%198 528
MERCK & CO., INC.-5.29%196 100
ABBVIE INC.0.71%190 442